Lupin rises on launching Generic Ranolazine ER Tablets in US

28 Feb 2019 Evaluate

Lupin is currently trading at Rs. 770.00, up by 2.30 points or 0.30% from its previous closing of Rs. 767.70 on the BSE.

The scrip opened at Rs. 765.80 and has touched a high and low of Rs. 773.60 and Rs. 765.80 respectively. So far 19266 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 723.55 on 15-May-2018.

Last one week high and low of the scrip stood at Rs. 786.65 and Rs. 764.00 respectively. The current market cap of the company is Rs. 34979.21 crore.

The promoters holding in the company stood at 46.98%, while Institutions and Non-Institutions held 38.84% and 14.18% respectively.

Lupin has launched Ranolazine Extended-Release (ER) Tablets, 500mg and 1000mg. The company’s Ranolazine ER Tablets, 500mg and 1000mg are a generic version of Gilead Sciences, Inc.'s Ranexa ER Tablets, 500mg and 1000mg. Ranolazine is indicated for the treatment of chronic angina.

Ranolazine ER Tablets, 500mg and 1000mg had an annual sales of approximately $ 945 million in the US (IQVIA MAT December 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×